(NASDAQ: MDGL) Madrigal Pharmaceuticals's forecast annual revenue growth rate of 76.59% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Madrigal Pharmaceuticals's revenue in 2025 is $317,383,000.On average, 5 Wall Street analysts forecast MDGL's revenue for 2025 to be $15,036,684,262, with the lowest MDGL revenue forecast at $13,309,757,395, and the highest MDGL revenue forecast at $16,579,190,669. On average, 5 Wall Street analysts forecast MDGL's revenue for 2026 to be $24,489,864,793, with the lowest MDGL revenue forecast at $20,969,667,652, and the highest MDGL revenue forecast at $29,283,908,630.
In 2027, MDGL is forecast to generate $39,775,847,506 in revenue, with the lowest revenue forecast at $36,171,366,706 and the highest revenue forecast at $44,701,867,651.